Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: A single-centre, real-world experience

Rheumatology (United Kingdom)

Volumn 53, Issue 4, 2014, Pages 665-670

  Russo, Ricardo A G ^a   Melo gomes, Sonia ^a   Lachmann, Helen J ^b   Wynne, Karen ^a   Rajput, Kaukab ^c   Eleftheriou, Despina ^a   Edelsten, Clive ^a   Hawkins, Philip N ^b   Brogan, Paul A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Autoinflammatory; Canakinumab; CAPS; CINCA NOMID; Muckle Wells

Indexed keywords

ACUTE PHASE PROTEIN; CANAKINUMAB;

ARTICLE; BODY HEIGHT; CHICKENPOX; CHILD; CHILD GROWTH; CHILD HEALTH ASSESSMENT QUESTIONNAIRE; CHILD HEALTH QUESTIONNAIRE PARENT FORM 28; CINCA SYNDROME; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL PRACTICE; DISABILITY; DISEASE ACTIVITY SCORE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROENTERITIS; HEARING; HUMAN; MALE; MUCKLE WELLS SYNDROME; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE;

AUTOINFLAMMATORY; CANAKINUMAB; CAPS; CINCA/NOMID; MUCKLE-WELLS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FEMALE; HEMOGLOBINS; HUMANS; INTERLEUKIN-1BETA; MALE; SERUM AMYLOID A PROTEIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84897841040     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket415     Document Type: Article

References (18)

1. Aksentijevich I, Putnam D, Remmers EF et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56:1273-85.
2. Lachmann HJ, Goodman HJ, Gilbertson JA et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71.
3. Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009;206:1029-36.
4. Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92.
5. Hawkins PN, Lachmann HJ, Aganna E et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12.
6. Hoffman HM, Throne ML, Amar NJ et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-52.
7. Leslie KS, Lachmann HJ, Bruning E et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-7.
8. Alten R, Gram H, Joosten LA et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R67.
9. Kuemmerle-Deschner JB, Hachulla E et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011;70:2095-102.
10. Kuemmerle-Deschner JB, Ramos E, Blank N et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther 2011;13:R34.
11. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
12. Caorsi R, Lepore L, Zulian F et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther 2013;15:R33.
13. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011;63:840-9.
14. Singh G, Athreya BH, Fries JF et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9.
15. Landgraf JM, Maunsell E, Speechley KN et al. Canadian- French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Qual Life Res 1998;7:433-45.
16. Pan H, Cole TJ. LMSgrowth, a Microsoft Excel add-on to access growth references based on the LMS method2011, Version 2.76. http://www.healthforallchil dren.co.uk/(1 March 2013, date last accessed).
17. Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB et al. Sustained remission of symptoms and improved healthrelated quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011;13:R202.
18. Imagawa T, Nishikomori R, Takada H et al. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 2013;31:302-9.